Additional Ventures: Investing in Congenital Heart Disease Research to Advance CareAdditional Ventures: Investing in Congenital Heart Disease Research to Advance Care https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Katie Brind'Amour, PhD, MS, CHES Katie Brind'Amour, PhD, MS, CHES https://pediatricsnationwide.org/wp-content/uploads/2021/03/Katie-B-portrait.gif
- October 06, 2021
- Katie Brind'Amour, PhD, MS, CHES
Additional Ventures is a purpose-driven nonprofit that has developed the Single Ventricle Research Fund (SVRF), an annual research award program dedicated to accelerating research and improving care for people with single ventricle heart defects. The fund supports investigators through multi-year, high-impact grants focused on different elements in their carefully structured research roadmap.
By funding investigators focused on key areas of the development and amelioration of single ventricle congenital heart disease (SF CHD), Additional Ventures aims to make single ventricle defects better understood and more treatable.
In 2020, Nationwide Children’s received a $1 million Innovation Fund endowed by Additional Ventures, joining a handful of other research institutions in a large-scale coordinated effort to find new ways to functionally cure patients with SV CHD.
Nationwide Children’s awarded portions of the Additional Ventures funding to three projects:
- Elucidating Mechanisms of Ventricular Hypoplasia in PA-IVS Using Patient-Derived iPSCs
- Co-principal investigators Vidu Garg, MD, PhD, director of the Center for Cardiovascular Research at The Heart Center, and Mingtao Zhao, DVM, PhD, principal investigator in the Center for Cardiovascular Research
- Development of a Protocol to Risk Stratify Individuals With Single Ventricle Congenital Heart Disease Using Deep Phenotyping and Genome Sequencing
- Co-principal investigators Kim McBride, MD, MS, division chief of Genetic and Genomic Medicine, and Peter White, PhD, senior director of Computational Genomics
- Unlocking Our Regenerative Capacity: Elucidating the Role of LYST on Neotissue Formation in Tissue Engineered Constructs
- Co-principal investigators Christopher Breuer, MD, director of the Center for Regenerative Medicine, and Rick Wilson, PhD, executive director of the Institute for Genomic Medicine
More information on Additional Ventures and their funded SV CHD studies can be found at AdditionalVentures.org.
This article appears in the Fall/Winter 2021 print issue. Download the full issue.
Image credits: Nationwide Children’s
To learn more about CHD research at Nationwide Children’s, read How Patient-Derived Stem Cells are Changing the Trajectory of Congenital Heart Disease Research.
About the author
- Posted In:
- In Brief
You might also like
Congenital Heart Disease and Extracardiac Phenotypes Associated With Novel Pathogenic Variant in GATA6Congenital Heart Disease and Extracardiac Phenotypes Associated With Novel Pathogenic Variant in GATA6 https://pediatricsnationwide.org/wp-content/uploads/2022/07/AdobeStock_134232290-DNA-header-1024x575-1.gif 1024 575 Jessica Nye, PhD Jessica Nye, PhD https://secure.gravatar.com/avatar/?s=96&d=mm&r=g
Racial Disparities in Healthcare Use Among Medicaid-Covered Children With Congenital Heart DiseaseRacial Disparities in Healthcare Use Among Medicaid-Covered Children With Congenital Heart Disease https://pediatricsnationwide.org/wp-content/uploads/2023/09/AdobeStock_498105881-1024x683.png 1024 683 Lauren Dembeck Lauren Dembeck https://pediatricsnationwide.org/wp-content/uploads/2021/03/Dembeck_headshot.gif
Counseling Families of Patients with Hypoplastic Left Heart SyndromeCounseling Families of Patients with Hypoplastic Left Heart Syndrome https://pediatricsnationwide.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 Mary Bates, PhD Mary Bates, PhD https://secure.gravatar.com/avatar/c6233ca2b7754ab7c4c820e14eb518c8?s=96&d=mm&r=g